Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is a leading provider of value-based care solutions in the healthcare industry. With its integrated platform for health plan administration and population health management, as well as its expertise in specialty care, Evolent is well-positioned to benefit from the growing trend towards value-based care. The company's recent divestitures have streamlined its focus and strengthened its financials, while its partnerships with major healthcare players provide a strong foundation for future growth. As the healthcare industry continues to evolve, Evolent Health is poised for success as a key player in the value-based care paradigm.

Bears say

Evolent Health is focused on providing value-based care and population health management solutions, but its recent financial results and guidance have not been promising. The company's 2026 revenue and earnings forecast were raised, but it also introduced 2027 targets that included a significant decline in revenue from its technology and services segment due to market exits and client-specific membership attrition. Additionally, the company has faced challenges with new contracts, including a potential drag on earnings from new signings and the need to establish reserves for a new $300 million oncology contract expected to start in December. Despite some recent positive developments, the company's outlook remains uncertain and there is risk around its long-term profitability.

Evolent Health (EVH) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 12 analysts, Evolent Health (EVH) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.